CN102665752B - 泌酸调节肽类似物 - Google Patents

泌酸调节肽类似物 Download PDF

Info

Publication number
CN102665752B
CN102665752B CN201080058422.4A CN201080058422A CN102665752B CN 102665752 B CN102665752 B CN 102665752B CN 201080058422 A CN201080058422 A CN 201080058422A CN 102665752 B CN102665752 B CN 102665752B
Authority
CN
China
Prior art keywords
oxm
cys
peptide
seq
asn
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201080058422.4A
Other languages
English (en)
Chinese (zh)
Other versions
CN102665752A (zh
Inventor
J·阿尔西纳-费尔南德斯
W·D·科恩
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43568014&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN102665752(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Publication of CN102665752A publication Critical patent/CN102665752A/zh
Application granted granted Critical
Publication of CN102665752B publication Critical patent/CN102665752B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
CN201080058422.4A 2009-12-22 2010-12-15 泌酸调节肽类似物 Active CN102665752B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US28888409P 2009-12-22 2009-12-22
US61/288,884 2009-12-22
US35256910P 2010-06-08 2010-06-08
US61/352,569 2010-06-08
PCT/US2010/060380 WO2011087671A1 (en) 2009-12-22 2010-12-15 Oxyntomodulin peptide analogue

Publications (2)

Publication Number Publication Date
CN102665752A CN102665752A (zh) 2012-09-12
CN102665752B true CN102665752B (zh) 2015-01-21

Family

ID=43568014

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201080058422.4A Active CN102665752B (zh) 2009-12-22 2010-12-15 泌酸调节肽类似物

Country Status (26)

Country Link
US (1) US8415296B2 (cg-RX-API-DMAC7.html)
EP (1) EP2515927B1 (cg-RX-API-DMAC7.html)
JP (1) JP5717758B2 (cg-RX-API-DMAC7.html)
KR (1) KR101399692B1 (cg-RX-API-DMAC7.html)
CN (1) CN102665752B (cg-RX-API-DMAC7.html)
AR (1) AR079344A1 (cg-RX-API-DMAC7.html)
AU (1) AU2010341650B2 (cg-RX-API-DMAC7.html)
BR (1) BR112012017054A2 (cg-RX-API-DMAC7.html)
CA (1) CA2784668C (cg-RX-API-DMAC7.html)
CL (1) CL2012001685A1 (cg-RX-API-DMAC7.html)
CO (1) CO6551737A2 (cg-RX-API-DMAC7.html)
CR (1) CR20120339A (cg-RX-API-DMAC7.html)
DO (1) DOP2012000175A (cg-RX-API-DMAC7.html)
EA (1) EA201290557A1 (cg-RX-API-DMAC7.html)
EC (1) ECSP12011988A (cg-RX-API-DMAC7.html)
ES (1) ES2512141T3 (cg-RX-API-DMAC7.html)
GT (1) GT201200205A (cg-RX-API-DMAC7.html)
MA (1) MA33826B1 (cg-RX-API-DMAC7.html)
MX (1) MX2012007449A (cg-RX-API-DMAC7.html)
NZ (1) NZ600732A (cg-RX-API-DMAC7.html)
PE (1) PE20121721A1 (cg-RX-API-DMAC7.html)
SG (1) SG181872A1 (cg-RX-API-DMAC7.html)
TN (1) TN2012000303A1 (cg-RX-API-DMAC7.html)
TW (1) TWI451873B (cg-RX-API-DMAC7.html)
UA (1) UA106399C2 (cg-RX-API-DMAC7.html)
WO (1) WO2011087671A1 (cg-RX-API-DMAC7.html)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
DK2049081T3 (da) 2006-08-09 2013-02-25 Intarcia Therapeutics Inc Osmotiske leveringssystemer og stempelarrangementer
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
PL2157967T3 (pl) 2007-04-23 2013-06-28 Intarcia Therapeutics Inc Formulacje zawiesinowe peptydów insulinotropowych i ich zastosowania
US8980830B2 (en) 2007-10-30 2015-03-17 Indiana University Research And Technology Corporation Peptide compounds exhibiting glucagon antagonist and GLP-1 agonist activity
ES2509883T3 (es) 2007-10-30 2014-10-20 Indiana University Research And Technology Corporation Antagonistas de glucagón
CA2726861C (en) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Devices, formulations, and methods for delivery of multiple beneficial agents
WO2010011439A2 (en) 2008-06-17 2010-01-28 Indiana University Research And Technology Corporation Gip-based mixed agonists for treatment of metabolic disorders and obesity
AU2009327418A1 (en) 2008-12-19 2010-06-24 Indiana University Research And Technology Corporation Amide based glucagon superfamily peptide prodrugs
US9150632B2 (en) 2009-06-16 2015-10-06 Indiana University Research And Technology Corporation GIP receptor-active glucagon compounds
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
NZ598686A (en) 2009-09-28 2014-05-30 Intarcia Therapeutics Inc Rapid establishment and/or termination of substantial steady-state drug delivery
AR079345A1 (es) * 2009-12-22 2012-01-18 Lilly Co Eli Analogo peptidico de oxintomodulina
US8551946B2 (en) 2010-01-27 2013-10-08 Indiana University Research And Technology Corporation Glucagon antagonist-GIP agonist conjugates and compositions for the treatment of metabolic disorders and obesity
US9145451B2 (en) 2010-05-13 2015-09-29 Indiana University Research And Technology Corporation Glucagon superfamily peptides exhbiting G protein coupled receptor activity
JP6121323B2 (ja) 2010-05-13 2017-05-10 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 核内ホルモン受容体の活性を示すグルカゴンスーパーファミリーのペプチド
PE20140186A1 (es) 2010-12-22 2014-02-13 Univ Indiana Res & Tech Corp Analogos de glucagon que presentan actividad de receptor de gip
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
EP2714070B1 (en) * 2011-06-02 2024-03-20 OPKO Biologics Ltd. Long-acting glp-1/glucagon receptor agonists
US10166295B2 (en) 2011-06-02 2019-01-01 Opko Biologics Ltd. Pegylated OXM variants
SI2718318T1 (sl) 2011-06-10 2018-11-30 Hanmi Science Co., Ltd. Novi derivati oksintomodulina in le-te obsegajoča farmacevtska sestava za zdravljenje debelosti
ES2710356T3 (es) 2011-06-17 2019-04-24 Hanmi Science Co Ltd Conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
JP6179864B2 (ja) 2011-06-22 2017-08-16 インディアナ ユニヴァーシティ リサーチ アンド テクノロジー コーポレイション グルカゴン／ｇｌｐ−１レセプタコ−アゴニスト
CN103748109A (zh) 2011-06-22 2014-04-23 印第安纳大学研究及科技有限公司 胰高血糖素/glp-1受体共同激动剂
EP2780031B1 (en) 2011-11-17 2018-03-07 Indiana University Research and Technology Corporation Glucagon superfamily peptides exhibiting glucocorticoid receptor activity
SG11201406671RA (en) * 2012-04-19 2014-11-27 Opko Biolog Ltd Long-acting oxyntomodulin variants and methods of producing same
JP6290193B2 (ja) 2012-06-04 2018-03-07 オプコ バイオロジクス リミテッド ペグ化ｏｘｍ変異体
EP2864351B1 (en) 2012-06-21 2016-08-10 Indiana University Research and Technology Corporation Glucagon analogs exhibiting gip receptor activity
KR101968344B1 (ko) 2012-07-25 2019-04-12 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 고지혈증 치료용 조성물
WO2014049610A2 (en) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides as gip, glp-1 and glucagon receptors triple-agonist
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
TWI652071B (zh) 2012-11-06 2019-03-01 韓美藥品股份有限公司 包含調酸素及免疫球蛋白片段之蛋白質接合物的液態製劑
KR101993393B1 (ko) 2012-11-06 2019-10-01 한미약품 주식회사 옥신토모듈린 유도체를 포함하는 당뇨병 또는 비만성 당뇨병 치료용 조성물
CA2895875A1 (en) 2012-12-21 2014-06-26 Sanofi Exendin-4 derivatives
CN105431447A (zh) * 2013-03-15 2016-03-23 阿达拉塔合伙有限公司 Pcsk9的小分子调节剂和其使用方法
US20150158926A1 (en) 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
WO2015086730A1 (en) 2013-12-13 2015-06-18 Sanofi Non-acylated exendin-4 peptide analogues
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
EP3080154B1 (en) 2013-12-13 2018-02-07 Sanofi Dual glp-1/gip receptor agonists
EP3080150B1 (en) 2013-12-13 2018-08-01 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
TWI802396B (zh) 2014-09-16 2023-05-11 南韓商韓美藥品股份有限公司 長效glp-1/高血糖素受體雙促效劑治療非酒精性脂肝疾病之用途
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2943359T3 (es) 2014-12-10 2023-06-12 Opko Biologics Ltd Métodos de producción de polipéptidos de hormona de crecimiento modificados con CTP de acción prolongada
KR102418477B1 (ko) 2014-12-30 2022-07-08 한미약품 주식회사 글루카곤 유도체
AU2016270984B2 (en) 2015-06-03 2021-02-25 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
WO2016198628A1 (en) 2015-06-12 2016-12-15 Sanofi Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists
WO2016198624A1 (en) 2015-06-12 2016-12-15 Sanofi Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
TWI622596B (zh) 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US11976106B2 (en) 2016-07-11 2024-05-07 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
TW201832783A (zh) 2016-12-02 2018-09-16 法商賽諾菲公司 包含ｇｌｐ－１／胰高血糖素雙重激動劑、連接子和透明質酸的接合物
CN110225762A (zh) 2017-01-03 2019-09-10 因塔西亚制药公司 包括glp-1受体激动剂的连续施用和药物的共同施用的方法
CN108299554B (zh) * 2017-01-13 2021-05-25 博瑞生物医药（苏州）股份有限公司 胃泌酸调节素类似物
CN106986924A (zh) * 2017-03-23 2017-07-28 中国药科大学 胃泌酸调节素（oxm）类似物及其应用
US12441776B2 (en) 2018-11-30 2025-10-14 Eirgen Pharma Ltd. Oxyntomodulin peptide analog formulations
KR102154959B1 (ko) * 2020-04-29 2020-09-10 동아에스티 주식회사 지속형 glp-1 및 글루카곤 수용체 이중작용제
WO2025169190A2 (en) 2024-02-06 2025-08-14 Opko Biologics Ltd. Modified oxyntomodulin and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134340A3 (en) * 2005-06-13 2007-06-28 Imp Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
CN101389648A (zh) * 2006-02-22 2009-03-18 默克公司 肽胃泌酸调节素衍生物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5445090A (en) 1991-07-25 1995-08-29 Mim Industries, Inc. Interchangeable clamp for use in a sewing machine
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
US6214966B1 (en) 1996-09-26 2001-04-10 Shearwater Corporation Soluble, degradable poly(ethylene glycol) derivatives for controllable release of bound molecules into solution
US6448369B1 (en) 1997-11-06 2002-09-10 Shearwater Corporation Heterobifunctional poly(ethylene glycol) derivatives and methods for their preparation
EP1061954B1 (en) 1998-03-12 2004-06-09 Nektar Therapeutics Al, Corporation Poly(ethylene glycol) derivatives with proximal reactive groups
DK1259562T3 (da) 1999-12-22 2006-04-18 Nektar Therapeutics Al Corp Sterisk hindrede derivater af vandoplöselige polymerer
US6413507B1 (en) 1999-12-23 2002-07-02 Shearwater Corporation Hydrolytically degradable carbamate derivatives of poly (ethylene glycol)
US6436386B1 (en) 2000-11-14 2002-08-20 Shearwater Corporation Hydroxyapatite-targeting poly (ethylene glycol) and related polymers
GB0121709D0 (en) 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
GB0300571D0 (en) 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
JP2006520818A (ja) 2003-03-19 2006-09-14 イーライ リリー アンド カンパニー ポリエチレングリコール結合ｇｌｐ−１化合物
ATE482724T1 (de) 2005-05-13 2010-10-15 Lilly Co Eli Pegylierte glp-1-verbindungen
ES2572952T3 (es) 2005-11-07 2016-06-03 Indiana University Research And Technology Corporation Análogos de glucagón que muestran solubilidad y estabilidad fisiológicas
TWI428346B (zh) 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
MX2009008241A (es) 2007-02-15 2009-10-08 Univ Indiana Res & Tech Corp Co-agonistas de receptor de glucagon/glp-1.
DK2158214T3 (da) 2007-06-15 2011-12-05 Zealand Pharma As Glukagonanaloger
WO2009030771A1 (en) * 2007-09-05 2009-03-12 Novo Nordisk A/S Peptides derivatized with a-b-c-d- and their therapeutical use
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006134340A3 (en) * 2005-06-13 2007-06-28 Imp Innovations Ltd Oxyntomodulin analogues and their effects on feeding behaviour
CN101389648A (zh) * 2006-02-22 2009-03-18 默克公司 肽胃泌酸调节素衍生物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
胃泌酸调节素研究进展;罗艳娜等;《动物医学进展》;20090420;第30卷(第4期);87-89 *

Also Published As

Publication number Publication date
KR101399692B1 (ko) 2014-05-27
MX2012007449A (es) 2012-11-23
WO2011087671A1 (en) 2011-07-21
AU2010341650B2 (en) 2014-03-27
EP2515927B1 (en) 2014-08-06
CL2012001685A1 (es) 2012-11-23
UA106399C2 (ru) 2014-08-26
CA2784668A1 (en) 2011-07-21
US8415296B2 (en) 2013-04-09
ECSP12011988A (es) 2012-07-31
AU2010341650A1 (en) 2012-06-07
SG181872A1 (en) 2012-07-30
DOP2012000175A (es) 2012-08-31
PE20121721A1 (es) 2012-12-17
HK1170943A1 (en) 2013-03-15
NZ600732A (en) 2014-06-27
TW201143792A (en) 2011-12-16
CR20120339A (es) 2012-10-02
US20110152181A1 (en) 2011-06-23
EA201290557A1 (ru) 2012-12-28
CA2784668C (en) 2015-05-05
ES2512141T3 (es) 2014-10-23
BR112012017054A2 (pt) 2016-11-22
JP5717758B2 (ja) 2015-05-13
JP2013515055A (ja) 2013-05-02
TWI451873B (zh) 2014-09-11
KR20120096023A (ko) 2012-08-29
CN102665752A (zh) 2012-09-12
EP2515927A1 (en) 2012-10-31
TN2012000303A1 (en) 2013-12-12
AR079344A1 (es) 2012-01-18
CO6551737A2 (es) 2012-10-31
MA33826B1 (fr) 2012-12-03
GT201200205A (es) 2014-04-08

Similar Documents

Publication Publication Date Title
CN102665752B (zh) 泌酸调节肽类似物
CN102740873B (zh) 泌酸调节肽类似物
TWI783244B (zh) 升糖素及glp-1共激動劑化合物
CN108348583B (zh) 胰高血糖素受体激动剂
HK1170943B (en) Oxyntomodulin peptide analogue
HK1170941B (en) Oxyntomodulin peptide analogue

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant